Join the Immuno-Oncology Revolution
Harnessing immune cells to destroy cancer can be a powerful therapeutic strategy. Some tumors, however, evade our immune system. Our lab studies how cancer cells become resistant to immunotherapy with the goal to develop new treatments.
​
A recently recognized immune checkpoint consists of the production of extracellular adenosine. Our lab was one of the first to describe the importance of adenosine-producing enzymes CD73 and CD39 for cancer immune evasion, and is now at the forefront of defining the impact of adenosine and ecto-nucleotidases on cancer development.
​
We are also developing a pipeline for identifying new I-O targets using AI tools, annotated patient samples and animal cancer models. We are validating new targets and developing next-generation I-O therapeutic agents.
